论文部分内容阅读
石蒜内铵(又称AT-1840)是具有抗癌作用而无化疗药物副作用的新型药物。本文共收洽28例患者,分为3组:第Ⅰ组为Ⅲ、Ⅳ期卵巢癌患者,术时肿块未能切除,术后单用AT-1840;第2组为Ⅱ、Ⅲ期卵巢癌患者,病灶基本切除,术后未完成化疗而改用AT-1840;第3组为各期卵巢癌患者,术后常规化疗,于化疗间歇期加用AT-1840。总计28例的疗效为显效15例(54％),进步4例(14％),无效9例(32％)。
Lycolide (also known as AT-1840) is a novel drug with anticancer effects without the side effects of chemotherapy drugs. A total of 28 patients were enrolled in this study and divided into 3 groups: Group I patients with stage III and IV ovarian cancer. The tumors were not resected at the time of surgery and AT-1840 was used alone; the second group was stage II and stage III ovarian cancer. In patients, basic resection of the lesions was performed and AT-1840 was used after completion of chemotherapy. The third group consisted of patients with ovarian cancer at each stage. After routine chemotherapy, AT-1840 was added during the interval between chemotherapy. A total of 28 cases were markedly effective in 15 cases (54%), 4 cases (14%), and 9 cases (32%).